Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Table 2 Dose reductions and dose intensity

Chemotherapy	Dose reduction at initiation, no (%)	Dose reduction after initiation, no (%)	Median relative dose intensity (%)^a
Nab-paclitaxel	28 (100)	10 (35.7)	57.5
Gemcitabine	13 (46.4)	15 (53.6)	62.4

^aRelative dose intensity is the proportion of the administered cumulative dose relative to the planned cumulative dose of G 1000 mg/m² and Nab-P 125 mg/m² days 1, 8, and 15 every 4 weeks

ISSN: 2162-3619